Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A Herpes Simplex Virus-Derived Replicative Vector Expressing LIF Limits Experimental Demyelinating Disease and Modulates Autoimmunity.
Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).
Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNS.
Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta.
Demyelination: the role of reactive oxygen and nitrogen species.
Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic.
Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Effects of exercise in experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis).
UPDATE 2-FDA panel supports approval of Sanofi's MS drug Lemtrada
Chronic inflammatory demyelinating polyneuropathy following malignant melanoma.
Safety Study of GNbAC1 in Multiple Sclerosis Patients
Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.
Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells.
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE(R) 20 mg Suit
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study.
Medicare Part D payments for neurologist-prescribed drugs.
Tumefactive multiple sclerosis requiring emergent biopsy and histological investigation to confirm the diagnosis: a case report.
Endogenous opioids regulate the expression of inducible nitric oxide synthase by splenocytes.
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis
The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.
Phenytoin (Dilantin) and acupuncture therapy in the treatment of intractable oral and facial pain.
Receptos provides update on progress of lead product candidate RPC1063
Central motor conduction time may predict response to fampridine in patients with multiple sclerosis.
Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.

Pages